Brachytherapy (BT) provides excellent long-term outcomes for relatively young men with clinically localized prostate cancer (PCa), researchers reported.
In a study of 236 men aged 60 years or younger with clinically localized PCa, BT alone or in combination with external beam radiation therapy (EBRT) was associated with eight-year PSA relapse-free survival (RFS), cancer-specific survival, and overall survival rates of 96%, 99%, and 96%, respectively, according to findings published in BJU International (2013;111:1231-1236). BT-based approaches also were associated with a low risk of long-term genitourinary (GI) and gastrointestinal (GI) morbidities, with erectile function preserved in more than half of patients.